Polyphor stays above water after Sfr165m IPO
Swiss biopharmaceutical company Polyphor has bucked the trend of recent European IPOs by pricing its IPO at Sfr38, in the top half of the initial Sfr30 to Sfr40 range, and increasing the size of the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: